1 results match your criteria: "Immunology and Immunotherapy Direction. Center of Molecular Immunology[Affiliation]"
Oxidative refolding by Copper-catalyzed air oxidation consistently increases the homogeneity and activity of a Novel Interleukin-2 mutein.
J Biotechnol
September 2024
Immune-regulation Department, Immunology and Immunotherapy Direction. Center of Molecular Immunology, PO Box 16040, Havana, Cuba. Electronic address:
Article Synopsis
- Interleukin-2 (IL-2) has been used for cancer treatment for over 30 years, but high toxicity has led to the development of mutant variants with lower toxicity and enhanced therapeutic benefits.
- The Center of Molecular Immunology has created a new variant called IL-2 no-alpha mutein, which is currently undergoing a Phase I/II clinical trial and is produced in E. coli through a process that requires refolding.
- A new purification method involving copper-catalyzed air oxidation ensures proper disulfide bond formation, resulting in a protein with improved 3D structure, higher purity, and greater biological activity compared to previous methods.